NCT02248597View on ClinicalTrials.gov

Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 25, 2015

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2023

Conditions

Graft Versus Host DiseaseHematopoietic/Lymphoid Cancer

Interventions

DRUG

fludarabine phosphate

Given IV

DRUG

busulfan

Given IV

DRUG

cyclophosphamide

Given IV

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Undergo myeloablative or reduced intensity allogeneic stem cell transplant

DRUG

tacrolimus

DRUG

mycophenolate mofetil

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02248597 - Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases | Biotech Hunter | Biotech Hunter